Medivolve Announces Webinar Introducing Newest Partners Marvel Diagnostics, Startup Out of UCLA - Seite 2

Nachrichtenquelle: globenewswire
01.02.2021, 18:33  |  318   |   |   

The BlowFISH collector will be compatible with existing and emerging POC diagnostic test systems, such as an rtPCR-based test. It is a simple matter of extracting the exhaled breath condensate from the collection zone and shipping it off for diagnostic testing.

COVID-19 Research Disclaimer: Medivolve cautions that this research is still early-stage research and development and is not making any express or implied claims that it has or will have the ability to detect the SARS-CoV-2 virus at this time. Further, Medivolve cautions that it is not making any express or implied claims that the device(s) or technology will have successful clinical study results or be in a position to obtain FDA approvals required to commercialize the technology.

About Marvel Diagnostics Inc.

Marvel Diagnostics Inc. is a company focused on the commercialization of the novel BlowFISH technology developed by its UCLA-based research team funded by NSF-RAPID and NIH. The Marvel Diagnostics research team led by Pirouz Kavehpour (Professor, UCLA) with Jonathan Rothstein (Professor, UMass-Amherst) and Jeff Ruberti (Professor, Northeastern U.), all former lab mates at Massachusetts Institute of Technology nearly 20 years ago. Moving forward, Leyla Mirmomen (PhD/MBA) is the executive who will lead the commercialization of the technology and run the company.

The Marvel Diagnostics team also has several medical experts at UCLA’s hospital serving as consultants for infectious disease, FDA clearance and clinical trials. Marvel Diagnostics will leverage an existing partnership with UCLA to develop the technology.

About Collection Sites

Collection Sites COVID-19 testing centers offer convenient access to rapid antibody and antigen tests - which take 8-10 minutes to administer and provide results in less than 24 hours. The sites also offer regular RT-PCR. The testing centres are powered by Alcala Testing and Analysis Services, a CLIA-licensed laboratory based in San Diego, California. All tests can be administered with insurance coverage options. The tests results can be communicated via text or email and can be accompanied with a certificate of good health via a HIPAA-compliant smartphone application.

Seite 2 von 4
Medivolve Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf


0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren



Medivolve Announces Webinar Introducing Newest Partners Marvel Diagnostics, Startup Out of UCLA - Seite 2 Medivolve will host a webinar Thursday, February 4th at 1 pm ET. This includes an overview of Collection Sites’ network growth and a presentation from the UCLA researchers behind the Marvel Diagnostics innovative BlowFISH Technology for …


Nachrichten des Autors


Nachrichten zu den Werten